The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures
- 264 Downloads
Pregnancy prevention programmes (PPPs) exist for some medicines known to be highly teratogenic. It is increasingly recognised that the impact of these risk minimisation measures requires periodic evaluation. This study aimed to assess the extent to which some of the data needed to monitor the effectiveness of PPPs may be present in European healthcare databases.
An inventory was completed for databases contributing to EUROmediCAT capturing pregnancy and prescription data in Denmark, Norway, the Netherlands, Italy (Tuscany/Emilia Romagna), Wales and the rest of the UK, to determine the extent of data collected that could be used to evaluate the impact of PPPs.
Data availability varied between databases. All databases could be used to identify the frequency and duration of prescriptions to women of childbearing age from primary care, but there were specific issues with availability of data from secondary care and private care. To estimate the frequency of exposed pregnancies, all databases could be linked to pregnancy data, but the accuracy of timing of the start of pregnancy was variable, and data on pregnancies ending in induced abortions were often not available. Data availability on contraception to estimate compliance with contraception requirements was variable and no data were available on pregnancy tests.
Current electronic healthcare databases do not contain all the data necessary to fully monitor the effectiveness of PPP implementation, and thus, special data collection measures need to be instituted.
KeywordsPregnancy Teratogen Pregnancy prevention programme Electronic health records Isotretinoin
The authors wish to thank Professor Corinne de Vries for her valuable contribution to the initial stages of this work. The authors would also like to acknowledge the input from the EUROmediCAT Steering Group members who reviewed this paper.
This study was part of the EUROmediCAT research project (www.euromedicat.eu) which has been supported by the European Commission under the 7th Framework Programme Grant agreement n° 260598.
Compliance with ethical standards
Conflicts of interest
RA Charlton, HJ Bos, E Garne, AV Hansen, LTW de Jong-van den berg, S Jordan, K Klungsøyr, A Pierini, M Sinclair, D Thayer and H Dolk had financial support from the European Union for the submitted work under the 7th Framework Programme (Grant agreement HEALTH-F5-2011-260598). AJ Neville was paid as a consultant to the Retinoids Consensus Conference and works for the IMER Registry which is financed by the Emilia Romagna Health Authority. V Bettoli, A Engeland, R Gini and A Puccini have no conflicts of interest to report relevant to the content of this manuscript.
- 1.European Medicine Agency (EMA) (2017) Guideline on good pharmacovigilance practices (GVP) module V—risk management systems (Rev 2). [cited 2017 05 July]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
- 2.European Medicines Agency (2015) Towards optimising risk minimisation measures. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/12/WC500198810.pdf. Accessed 07.05.2017
- 3.Whitley L, Knight C, Gabbay F Risk minimisation and measuring effectiveness—the evolving challenge. Available from www.transcrip-partners.com/files/download/78. Accessed 07.07.2017
- 8.Roche Products (Ireland) Limited (2016) Roaccutane: pregnancy prevention programme. Physician’s guide to prescribing isotretinoin (Roaccutane) Available from https://www.hpra.ie/docs/default-source/3rd-party-documents/educational-materials/roaccutane-prescriber-guide.pdf?sfvrsn=2. Accessed 08/06/2016
- 9.Acitretin summary of product characteristics (2015) Available from http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1463720374780.pdf. Accessed 09.06/2016
- 12.Raguideau F, Mezzarobba M, Zureik M, Weill A, Ricordeau P, Alla F (2015) Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Pharmacoepidemiol Drug Saf 24(5):526–533. https://doi.org/10.1002/pds.3763 CrossRefPubMedGoogle Scholar
- 13.Henry D, Dormuth C, Winquist B, Carney G, Bugden S, Teare G, Lévesque LE, Bérard A, Paterson JM, Platt RW, CNODES (Canadian Network for Observational Drug Effect Studies) Investigators (2016) Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ: Can Med Assoc J 188(10):723–730. https://doi.org/10.1503/cmaj.151243 CrossRefGoogle Scholar
- 14.Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsøyr K, Andersen AMN, Hansen AV, Gini R, Bos JHJ, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-van den Berg LTW, de Vries CS (2014) Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf 23(6):586–594. https://doi.org/10.1002/pds.3613 CrossRefPubMedGoogle Scholar
- 20.Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT (2006) Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 113(5):559–568. https://doi.org/10.1111/j.1471-0528.2006.00927.x CrossRefPubMedGoogle Scholar
- 23.Klungsøyr K, Morken NH, Irgens L, Vollset SE, Skjærven R (2012) Secular trends in the epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors and perinatal survival. Paediatr Perinat Epidemiol 26(3):190–198. https://doi.org/10.1111/j.1365-3016.2012.01260.x CrossRefPubMedGoogle Scholar
- 24.Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M, on behalf of the EU-ADR consortium (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1–11. https://doi.org/10.1002/pds.2053 CrossRefPubMedGoogle Scholar
- 25.Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, Lei J, Sturkenboom M, on behalf of the EU-ADR consortium (2012) Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf 21(6):611–621. https://doi.org/10.1002/pds.3197 CrossRefPubMedGoogle Scholar
- 32.Medicines Healthcare products Regulatory Agency (2014) Guidance—isotretinoin for severe acne: uses and effects. Available from https://www.gov.uk/government/publications/isotretinoin-for-severe-acne-uses-and-effects/isotretinoin-for-severe-acne-uses-and-effects. Accessed 19.07.2017
- 33.Schaefer C, Meister R, Weber-Schoendorfer C (2010) Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 281(2):221–227. https://doi.org/10.1007/s00404-009-1112-2 CrossRefPubMedGoogle Scholar
- 34.de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, Neville AJ, Pierini A, Puccini A, Thayer DS, Tucker D, Vinkel Hansen A, Bakker MK (2015) Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study. Drug Saf 38(11):1083–1093. https://doi.org/10.1007/s40264-015-0321-9 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Lagan BM, Dolk H, White B, Uges DRA, Sinclair M (2014) Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Pharmacoepidemiol Drug Saf 23(4):411–418. https://doi.org/10.1002/pds.3565 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Crijns I, Mantel-Teeuwisse A, Bloemberg R, Pinas E, Straus S, de Jong-van den Berg L (2013) Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opin Drug Saf 12(1):29–38. https://doi.org/10.1517/14740338.2013.745850 CrossRefPubMedGoogle Scholar
- 39.Källén B (1999) Restriction of the use of drugs with teratogenic properties: Swedish experiences with isotretinoin. Teratology 60(2):53. https://doi.org/10.1002/(SICI)1096-9926(199908)60:2<53::AID-TERA2>3.0.CO;2-7 CrossRefPubMedGoogle Scholar
- 41.Crijns HJMJ, van Rein N, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LTW (2012) Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Pharmacoepidemiol Drug Saf 21(10):1060–1066. https://doi.org/10.1002/pds.3200 CrossRefPubMedGoogle Scholar
- 44.European Medicines Agency. Valproate and related substances and their use in pregnant women. [Cited 08/07/2016] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500175214.pdf. Accessed 07.07.2017